Voyager Therapeutics/$VYGR
1D1W1MYTD1Y5YMAX
About Voyager Therapeutics
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
- Ticker
- $VYGR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 141
- Headquarters
- Lexington, United States
- Website
- www.voyagertherapeutics.com
VYGR Metrics
BasicAdvanced
$203M
-
-$1.81
1.31
-
Price and volume
Market cap
$203M
Beta
1.31
52-week high
$5.55
52-week low
$2.94
Average daily volume
587K
Financial strength
Current ratio
7.505
Quick ratio
7.162
Long term debt to equity
16.642
Total debt to equity
21.096
Profitability
EBITDA (TTM)
-109.867
Gross margin (TTM)
-236.81%
Net profit margin (TTM)
-312.63%
Operating margin (TTM)
-329.92%
Effective tax rate (TTM)
-0.12%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
-27.34%
Return on equity (TTM)
-54.09%
Valuation
Price to revenue (TTM)
5.693
Price to book
1.31
Price to tangible book (TTM)
1.31
Price to free cash flow (TTM)
-1.616
Free cash flow yield (TTM)
-61.89%
Free cash flow per share (TTM)
-2.042
Growth
Revenue change (TTM)
-19.07%
Earnings per share change (TTM)
-2.61%
3-year revenue growth (CAGR)
-43.87%
10-year revenue growth (CAGR)
6.46%
3-year earnings per share growth (CAGR)
-8.09%
10-year earnings per share growth (CAGR)
-0.91%
What the Analysts think about VYGR
Analyst ratings (Buy, Hold, Sell) for Voyager Therapeutics stock.
VYGR Financial Performance
Revenues and expenses
VYGR Earnings Performance
Company profitability
VYGR News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.